Mike Cooper

Mike Cooper

Chair

Mike has been a Trustee since 2014 and was appointed Chair in 2023 and having been Deputy Chairman since 2016, bringing a wealth of experience from his many years working in the advertising industry. He sits on both the Nominations and Governance Sub Committee and the Investment Sub Committee at ARUK.

Mike started out at Saatchi & Saatchi in 1984 and has worked at Omnicom Group for the last 25 years, where he has held a variety of roles.

He became CEO of PHD Worldwide in 2007, a position he held for 12 years. Today PHD is one of the world’s fastest growing and most awarded media agencies. In 2019 Mike was appointed Group CEO of Omnicom Media Group across EMEA and Asia Pacific in 2019 and early in 2022 he became vice Chairman of Omnicom Europe.

Mike says: “Dementia has touched my family like many others. I am extremely passionate about creating hope for sufferers both current and future.”

 Nick Antill

Nick Antill

Nick is our Treasurer and was appointed as a Trustee in 2015.

After beginning his career in the oil industry, Nick spent many years in the City of London where he was employed as an equity investment analyst specialising in valuing assets and companies in the oil and gas sector. He now works as a consultant both to the energy and to the investment industries, and as a financial trainer.

Nick chairs the Investment Sub Committee of the Board and works closely with the Executive Director of Finance and Operations. He is also a member of the Board of EDoN, the Early Detection of Neurodegenerative diseases initiative, representing the interests of ARUK in promoting the success of that initiative.

Nick says: “Research into the causes and prevention of dementias is essential if we are to alleviate or cure these terrible conditions. My background is in finance, and I felt that I could best help Alzheimer’s Research UK with its strategic financial control and with its investment asset allocation. Both are proving to be hugely interesting and rewarding.”

 Giles Dennison

Giles Dennison

Giles joined the Board of Trustees in April 2017. He was formerly a Partner and head of the Corporate Group at the law firm Simmons & Simmons and is currently a Partner and head of the Technology M&A Group at Eversheds Sutherland, the international commercial law firm. 

Giles sits on the Audit and Risk Sub Committee and the Legacy Sub Committee of the board, bringing valuable legal expertise.  He is also a member of the Board of EDoN, the Early Detection of Neurodegenerative diseases initiative, representing the interests of ARUK in promoting the success of that initiative.

Giles says: “Dementia touches the lives of so many of us, and yet until recently lagged significantly behind many other medical conditions in terms of public understanding and support, so I became a trustee of Alzheimer’s Research UK in the hope that I could play some small part in changing that situation and by so doing help in the search for an end to the devastating impact of dementia."

 Dr Rupert Evenett MBE

Dr Rupert Evenett MBE

Dr Rupert Evenett is the chair of the Audit and Risk Sub Committee, which has oversight of all areas of financial audit, risk and compliance. He joined as a Trustee in 2014 and brings vast experience from investment and finance roles in the private and public sectors, as well as social investment and wide board experience in the charity and educational sectors. He is also a chartered accountant.

He plays a key role at Alzheimer’s Research UK working with different departments, to ensure there is strong oversight of all areas of risk and compliance. 

Rupert says: “Science and research have achieved so much in health that they are formidable creators of hope. I can’t think of a better contribution to human wellbeing than supporting their fight against dementia”.

 Dr Ruth McKernan CBE

Dr Ruth McKernan CBE

Ruth joined as a Trustee in 2018 and is one of our Scientific Trustees. As a neuroscientist with more than 25 years of research experience in the pharmaceutical industry, she brings valuable expertise to the Board particularly around our drug discovery work. Her previous roles include Senior Vice President at Pfizer and Head of the Merck Neuroscience Research Centre. She also spent three years as CEO of InnovateUK, the Government’s Innovation agency helping to create new businesses and drive economic growth. She is a Venture Partner with the Dementia Discovery Fund (DDF) and has co-founded four dementia-focused biotech companies in the last 3 years. She was awarded a CBE in 2013 for services to business, innovation and skills.

Ruth says: ‘"I am joining Alzheimer’s Research UK because we all know someone who has suffered from the disease. I just want to bring what I have to help".

 Caroline van den Brul MBE

Caroline van den Brul MBE

Caroline became a supporter of the work of Alzheimer’s Research UK during the time her husband and mother were both living with Alzheimer’s disease; she became a Trustee in 2017. She had a distinguished 30-year career with the BBC as a programme maker (credits include Horizon, Tomorrow’s World Hospital Watch and the Ri Christmas Lectures) and as the creativity leader for the implementation of an ambitious culture-change programme.  Currently she coaches scientists in communication skills.  

Caroline is Chair of our Inspire Fund Review Committee and also sits on the Audit and Risk Committee.

Caroline says: "Many previously deadly diseases are no longer life limiting, or even significantly life-changing. Alzheimer’s disease is not one of them - yet.  I want that to change. It is too late for my mother and my husband who both faded and then died with Alzheimer’s but it is not too late for some of those they loved.  I am a Trustee of Alzheimer’s Research UK because of them, and because I believe the only way to make Alzheimer’s a treatable condition is to fund the essential research.” 

 Shirley Cramer CBE

Shirley Cramer CBE

Shirley became a Trustee in 2014, after having been Interim Chief Executive of Alzheimer’s Research UK in 2012 for six months. She sits on our Nominations and Governance Committee and our Scientific Advisory Board, playing a key role in driving Alzheimer’s Research UK strategy and excellence. She is formerly Chief Executive of the Royal Society for Public Health and is an experienced voluntary sector leader in both the UK and the USA. She is a Commissioner of  the UK Food, Farming and Countryside Commission and Chair of the Rare Dementia Support Advisory Board at University College London.

Shirley says: "When my mother was diagnosed with Alzheimer’s Disease, I began to realise that dementia research was way behind other diseases like cancer. I felt there needed to be more of an urgency to prioritise dementia research, which is why I’m passionate about what Alzheimer’s Research UK does. I know there will be solutions in the future, such as new treatments and earlier diagnosis, and I’m really proud to be a part of it."

Amanda Farnsworth

Amanda Farnsworth

Amanda became a Trustee of Alzheimer’s Research UK in 2021. She sits on the Audit and Risk Sub Committee.

She has held some of the most high-profile leadership roles in the BBC including Editor of the TV One and Six O Clock News, Deputy Editor, Newsnight and Bureau Chief in Washington DC.

As Project Executive London 2012 she was involved in developing some of the BBC’s key external partnerships around the London 2012 Olympics including with The London Organising Committee and the London Mayor’s office. She sat on the BBC’s 2012 Steering Group, helping to formulate the BBC's vision, editorial strategy and plans to cover all the major 2012 events including the Olympic Torch Relay, the Cultural Olympiad and the Olympic Games. 

Amanda’s last job at the BBC was as Head of Visual and Data Journalism bringing together journalists, designers and developers to produce high impact, highly visual and personalised news across all domestic and global outlets on TV, social media and the web.

Amanda has extensive board experience in the charitable sector and is currently a Trustee at the Cambridge Arts Theatre, having spent six years on the board of the Lyric Theatre, Hammersmith. She was also a board member of the Global Editors Network and on the Advisory Board for a major piece of work on inequality at the Nuffield Foundation. She also chairs a volunteer-led group called Newcomers and Visiting Scholars at Cambridge University.

Amanda says “My family has been touched by dementia as have so many in this country and the world. Both my parents donated their brains to Alzheimer’s research and I too wanted to contribute to the cause of finding treatments and ultimately a cure for Dementia. I’m extremely proud to have become a Trustee at Alzheimer’s Research UK.”

 

Divya Chadha Manek OBE

Divya Chadha Manek OBE

Divya became a Trustee of Alzheimer’s Research UK in 2021. She sits on the Nominations and Governance Sub Committee.

Divya is currently Senior VP, Clinical Development at Eyebio, an opthalmology biotech company. In this role, Divya is responsible for the company’s clinical development strategy and execution.

Prior to this, Divya held various roles at the National Institute for Health Research (NIHR) having joined in 2007 most recently serving as the Clinical Research Network’s Director of Business Development and Marketing, leading a team responsible for increasing investment into UK health and social care research from both non-commercial and commercial research sponsors.

In 2020, Divya was seconded to the UK Vaccines Taskforce (VTF) which was set up in response to the COVID-19 pandemic to lead the UK’s search for a safe and effective vaccine. She was responsible for supporting global pharmaceutical companies to rapidly generate the evidence required for marketing authorisation of COVID-19 vaccines and played a pivotal role in conceptualising and developing the NHS Vaccine Research Registry. 

Divya holds a degree in Psychology, Royal Holloway and following this, was awarded an India academic scholarship to study a Masters of Clinical Research at University of Birmingham.  

Divya says:

“One of the greatest challenges we face as society is Dementia. Having started my career in clinical research, recruiting people with dementia and their families into studies, I have had first-hand experience of the devastation dementia causes families. Research is the way to fight this challenge. I am passionate about getting new treatments faster to patients through innovative research. ARUK is at the forefront of supporting innovative research and advancing science in dementia- I want to bring my skills and expertise to help”

Dr Catherine Elliott

Dr Catherine Elliott

Catherine joined our Board of Trustees in January 2024. Catherine is Director of Research and Partnerships at Cancer Research UK, a post she took up in August 2021, with responsibility for academic science and clinical research funding and partnerships. Prior to this role, Catherine spent six years at the University of Edinburgh as College Registrar for Medicine and Veterinary Medicine.

Catherine completed clinical academic training, and is an Honorary Consultant Obstetrician, with a Masters in Medical Law and Ethics. After completion of her specialist training, she worked at the Medical Research Council for ten years, in a range of posts including Director of Clinical Research Interests, Head of Neurosciences and Mental Health and policy lead for research regulation and governance.

Catherine says: “I am passionate about the importance of medical research to improve people’s lives and dementia is one of the greatest heath challenges that we face. I think the current progress towards effective interventions is very exciting and provides real hope that the impacts of different forms of dementia can be reduced.”

Clive Gringras

Clive Gringras

Clive joined our Board of Trustees in January 2024. He is partner at the law firm, CMS, heading its Band 1 Technology, Media & Telecoms team. He is one of seven lawyers in the Legal 500’s Hall of Fame for TMT and was honoured as Best Lawyer’s Technology Lawyer of the Year in 2021. His book, Gringras: The Laws of the Internet, now in sixth edition, is the only UK judicially-acclaimed text on the subject.

His prior role on the Board of EDoN and his current role as the Chair of Our Future Health’s Technology Advisory Board, underscore Clive’s dedication to advancing medical and technological research.


Clive says “I wanted to join Alzheimer’s Research UK as a Trustee because Alzheimer’s disease has personally affected my family, taking my wife’s grandmother, mother and recently her auntie. These painful experiences drove me to want to make a meaningful contribution to the charity and help find a cure before others are similarly struck. I can see the great potential of research into dementia, it’s key to unlocking the mysteries of this terrible condition.”

Prof Jeremy Chataway

Prof Jeremy Chataway

Jeremy joined our Board of Trustees in January 2024. He is Professor of Neurology at University College London and the National Hospital for Neurology and Neurosurgery (NHNN), Queen Square, University College Foundation NHS Trust.

After qualifying in medicine at Cambridge and Oxford Universities, and general medical training in London, he specialised in Neurology with posts in Edinburgh, Cambridge and London. He was awarded a PhD from Cambridge University in genetic epidemiology of multiple sclerosis and took up his post as a consultant Neurologist in 2001.

He has a particular interest in advanced clinical trial design and is the Chief Investigator of the MS-STAT, MS-SMART and OCTOPUS trial programmes in Progressive MS. He is a Programme Lead for Neurodegeneration at the MRC Clinical Trial Unit.

Jeremy says: “It’s a huge privilege to be chosen as a Trustee for Alzheimer's Research UK and I’m truly excited to get started. This moment really signifies a milestone in a personal journey to mark the memory of my mother Gill, who was affected by young-onset Alzheimer’s disease. As well as my own experience, I regularly see people with dementia in my general neurology clinic and know well, the ravages such a cruel condition can reap to the individual, the family and to society. That’s why I’m keen to support the search for a cure.”

Adrian Lovett

Adrian Lovett

Adrian joined our Board of Trustees in January 2024. Since 2022, Adrian Lovett has been Chief Executive Officer of Development Initiatives, an international non-profit organisation working to overcome poverty and inequality through better data and evidence.

He previously served as President and CEO of the World Wide Web Foundation for five years. Adrian was also a commissioner on the UN Broadband Commission and Co-chair of the World Economic Forum Council on the Connected World during this time. He held earlier leadership roles at ONE, Oxfam and Save the Children, as well as the Make Poverty History and Jubilee 2000 ‘Drop the Debt’ campaigns.

Adrian says: “Dementia affects my own family very directly, as it does so many families across the country. While this condition can be incredibly tough, there are so many reasons to be hopeful, as research uncovers new opportunities to treat, diagnose and prevent dementia. I'm optimistic about the difference we can make, but it's vital that we keep up the momentum in the search for a cure.”